Joseph Haas

5 days ago | insights.citeline.com | Joseph Haas

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF SpaceBMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer. Bristol places big bet on BioNTech's PD-L1xVEGF bispecific candidate • Source: Shutterstock

1 week ago | insights.citeline.com | Joseph Haas

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS. Akeso/Summit bispecific antibody demonstrates PFS in lung cancer setting • Source: Shutterstock

1 week ago | insights.citeline.com | Joseph Haas

Astellas Gets CLDN.18.2-Targeted ADC From China’s EvopointAstellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy. Astellas licenses Evopoint's CLDN18.2-targeted ADC • Source: Shutterstock

1 week ago | insights.citeline.com | Joseph Haas

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections. Spero, GSK may bring first oral antibiotic to cUTI patients (Shutterstock)

1 week ago | insights.citeline.com | Joseph Haas

Lilly To Diversify Pain Pipeline With SiteOne AcquisitionDeal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne. Lilly is acquiring SiteOne to add a non-opioid pain candidate to its pipeline (Shutterstock)